Recently, low Pitx2 expression was reported in patients with breast cancer [6, 7], prostate cancer [8, 9] and colon cancer [10], and it was considered as a potential predictor of poor clinical outcomes, which were correlated with its hypermethylation. The gene discussed is PITX2; the disease is prostate cancer.